]>
IRCT20200403046926N1 IRCT 2020-04-11 Mazandaran University of Medical Sciences The effect of SOVODAK in the treatment of COVID-19 patients The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study 2020-04-08 anticipated 60 Complete https://irct.ir/trial/46926 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be divided into two groups by Block Randomization. The block size is 4 people and a random list will be created by the sealedenvelope site. To hide the drugs, they are placed in the required number in the envelope. Then, according to the random codes created, one or two envelopes will be placed in a larger envelope. 3 COVID-19. Intervention 1: Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK. Intervention 2: Control group: COVID-19 Patients receiving hydroxychloroquine. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Fatemeh Roozbeh
Miandrood, Surak, Imam Khomeini St., Ashouri Medical Clinic
Sari Iran (Islamic Republic of) 4815733971 +98 11 3388 4579 roozbeh@mazums.ac.ir Mazandaran University of Medical Sciences scientific Fatemeh Roozbeh
Miandrood, Surak, Imam Khomeini St., Ashouri Medical Clinic
Sari Iran (Islamic Republic of) 4815733971 +98 11 3388 4579 roozbeh@mazums.ac.ir Mazandaran University of Medical Sciences Iran (Islamic Republic of) Diagnosis by CT scan with clinical symptoms Consent to attend the study Lymphocyte count less than 1100 Positive CRP test no limit no limit Both History of kidney failure Pregnancy Amiodarone consumer B34.2 Coronavirus infection, unspecified Treatment - Drugs Treatment - Drugs Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK Control group: COVID-19 Patients receiving hydroxychloroquine Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination. Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes. C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test. Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry. Need hospitalization. Timepoint: Depending on the situation. Method of measurement: Depending on the patient's condition. Mazandaran University of Medical Sciences Approved 2020-04-01 Ethics committee of Mazandaran University of Medical Sciences Miandrood Medical Center Sari Mazandaran Iran (Islamic Republic of)